Biocon Gets FDA Observations At Key Biosimilars Facilities
US Agency Finds Multiple Form 483 Deficiencies Across Bengaluru And Malaysia Sites
Biocon has revealed that an FDA inspection of key biosimilars manufacturing facilities in Bengaluru and Malaysia in August has resulted in numerous Form 483 observations across three Biocon Biologics sites.
